Zobrazeno 1 - 10
of 143
pro vyhledávání: ''
Autor:
Martin Gutierrez, Mark M. Awad, Joseph D. Szustakowski, Suresh S. Ramalingam, Jason Chesney, Justin F. Gainor, Neal Ready, Kim E. Zerba, Pavan S. Reddy, Ian Rabinowitz, Brian Lestini, Mihaela Mates, Xuemei Li, Martin Reck, James Michael Orcutt, George Green, Julie R. Brahmer, David R. Spigel, William J. Geese, Matthew D. Hellmann, Gregory A. Otterson, Kenneth J. O'Byrne, Jacques Jolivet, Wenhua Hu, Luis Paz-Ares, Leora Horn, Han Chang, Hossein Borghaei
Publikováno v:
Journal of Clinical Oncology
PURPOSE CheckMate 568 is an open-label phase II trial that evaluated the efficacy and safety of nivolumab plus low-dose ipilimumab as first-line treatment of advanced/metastatic non–small-cell lung cancer (NSCLC). We assessed the association of eff
Autor:
Céleste Lebbé, Merrick I. Ross, Axel Hauschild, Theodore F. Logan, Robert H.I. Andtbacka, John A. Glaspy, Philip Friedlander, Claus Garbe, Jason Chesney, Omid Hamid, Howard L. Kaufman, Parminder Singh, Jenny J. Kim, Frances A. Collichio, Jennifer Gansert, Mohammed M. Milhem, Lisa Chen, Igor Puzanov
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 36, iss 17
Purpose We evaluated the combination of talimogene laherparepvec plus ipilimumab versus ipilimumab alone in patients with advanced melanoma in a phase II study. To our knowledge, this was the first randomized trial to evaluate addition of an oncolyti
Autor:
Daniel M. Geynisman, Rebecca Slack, Lisa Pruitt, Matthew I. Milowsky, W. Kimryn Rathmell, Donna Juarez, Elshad Hasanov, Brian I. Rini, Nizar M. Tannir, Summer Stovall, Troy R. Gilchrist, Elizabeth R. Plimack, Moshe Chaim Ornstein, Eric Jonasch
Publikováno v:
Journal of Clinical Oncology. 36:1588-1593
Purpose Standard frontline treatment of patients with metastatic renal cell carcinoma currently includes sunitinib. A barrier to long-term treatment with sunitinib includes the development of significant adverse effects, including diarrhea, hand-foot
Autor:
Chris Jones, Frank Saran, Marie-Cécile Le Deley, Markus C. Elze, Lauren E. Abrey, Tim Jaspan, Helen Smith, Maura Massimino, Jacques Grill, Josep Garcia, Gilles Vassal, Raphael Rousseau, Felice Giangaspero, Paul S. Morgan, Amedeo A. Azizi, Geoffrey McCowage, Pascale Varlet, Eric Bouffet, Darren Hargrave, Adela Cañete
Publikováno v:
JOURNAL OF CLINICAL ONCOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Purpose Bevacizumab (BEV) is approved in more than 60 countries for use in adults with recurrent glioblastoma. We evaluated the addition of BEV to radiotherapy plus temozolomide (RT+TMZ) in pediatric patients with newly diagnosed high-grade glioma (H
Autor:
Helen Hatcher, Martee L. Hensley, Premal H. Thaker, David Miller, Krishnansu S. Tewari, Shashikant Lele, Katina Robison, Anders Krarup-Hansen, Cyril Fisher, Oliver Zivanovic, Katherine M. Moxley, Jayanthi S. Lea, David M. O'Malley, Danielle Enserro, Petronella B. Ottevanger, Jean-Yves Blay
Publikováno v:
Journal of Clinical Oncology, 36, 33, pp. 3324-3330
BASE-Bielefeld Academic Search Engine
Journal of Clinical Oncology, 36, 3324-3330
BASE-Bielefeld Academic Search Engine
Journal of Clinical Oncology, 36, 3324-3330
Purpose We conducted a randomized phase III trial to determine whether adjuvant chemotherapy improves survival in women with uterine leiomyosarcoma. Methods Women with uterus-confined, high-grade leiomyosarcoma who were confirmed disease free by imag
Autor:
Sarina Anne Piha-Paul, Shari Thomas, Hope S. Rugo, Emilie M.J. van Brummelen, Andrea Varga, Reshma A. Rangwala, Sanatan Saraf, Jean-Sebastien Frenel, Carlos Gomez-Roca, Christophe Le Tourneau, Patrick A. Ott, Bert H. O'Neil
Publikováno v:
Journal of Clinical Oncology. 35:4035-4041
Purpose The KEYNOTE-028 trial ( ClinicalTrials.gov identifier: NCT02054806) was designed to assess the safety and efficacy of pembrolizumab in 20 programmed death ligand 1–positive, advanced solid tumor cohorts. Here, we present the results from th
Autor:
Klaus Gellert, Georg Maschmeyer, Uwe Pelzer, Sven Bischoff, Marcus Bahra, Lutz Jacobasch, Helmut Oettle, Jana K. Striefler, Hanno Riess, Bettina Rau, Dirk Waldschmidt, Michael Ghadimi, Marianne Sinn, Robert Grützmann, Torsten Liersch, Bernd Dörken, Wolf O. Bechstein, Jens Stieler, Helmut Messmann, Arndt Weinmann, Martin Wilhelm
Publikováno v:
Journal of Clinical Oncology. 35:3330-3337
Purpose Gemcitabine is standard of care in the adjuvant treatment of resectable pancreatic ductal adenocarcinoma (PDAC). The epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in combination with gemcitabine has shown efficacy in th
Autor:
Ander Urruticoechea, Seock-Ah Im, Antonio Carlos Sánchez Ruiz, M. Rizwanullah, J Eng-Wong, István Láng, Montserrat Muñoz, Hannah Douthwaite, Gianluca Tomasello, Tanja Badovinac Crnjevic, Sarah Heeson
Publikováno v:
Journal of Clinical Oncology. 35:3030-3038
Purpose To assess the efficacy and safety of trastuzumab plus capecitabine with or without pertuzumab in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer who experienced disease progression during or after tr
Autor:
Paul G. Richardson, Hervé Avet-Loiseau, Benoit Dupas, Martine Escoffre-Barbe, Aurore Perrot, Eric Frampas, Caroline Bodet-Milin, Lotfi Benboubker, Michel Attal, Thierry Facon, Gerald Marit, Jean-Richard Eveillard, Florence Caillon, Cyrille Hulin, Véronique Dorvaux, Lionel Karlin, Carine Chaleteix, Denis Caillot, Anne-Marie Stoppa, Brigitte Pegourie, Philippe Moreau, Kamel Laribi, Laurent Garderet, Jean-Michel Nguyen, Nikhil C. Munshi, Kenneth C. Anderson, Aurélie Gaultier, Margaret Macro, Françoise Kraeber-Bodéré
Publikováno v:
Journal of Clinical Oncology. 35:2911-2918
Purpose Magnetic resonance imaging (MRI) and positron emission tomography–computed tomography (PET-CT) are important imaging techniques in multiple myeloma (MM). We conducted a prospective trial in patients with MM aimed at comparing MRI and PET-CT
Autor:
Darren R. Feldman, Toni K. Choueiri, Joel Picus, Ben L. Sanford, Olwen Hahn, M. Dror Michaelson, Shaker R. Dakhil, Daniel J. George, Meghara K. Walsh, Thomas Olencki, Eric J. Small, Susan Halabi, Michael J. Morris
Publikováno v:
Journal of Clinical Oncology. 35:591-597
Purpose Cabozantinib is an oral potent inhibitor of vascular endothelial growth factor receptor 2, MET, and AXL and is a standard second-line therapy for metastatic renal cell carcinoma (mRCC). This randomized phase II multicenter trial evaluated cab